Study of AGEN1571 in Participants With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 1, 2-part study to determine the recommended phase 2 dose (RP2D)
and evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of
AGEN1571 both as a monotherapy and in combination with balstilimab and/or botensilimab
(2-agent combination or 3-agent combination) in participants diagnosed with advanced solid
tumors.
Part 1 will be the dose escalation phase to determine the RP2D of AGEN1571 monotherapy or
AGEN1571 in combination with balstilimab and/or botensilimab. Part 2 will be the dose
expansion phase for specific disease indications. Participants will receive study treatment
for up to 2 years, or until any disease progression, unacceptable toxicity, or participant
wishes to withdraw consent for any reason.